Press Releases

Our latest press releases are available to read in this section

Press Releases

Date Range

Explore

Search

Press Releases / 04 Nov 2019

Summit Therapeutics Recognises C. difficile Awareness Month

Press Releases / 16 Oct 2019

Summit Therapeutics to Present at the 2019 BIO Investor Forum

Press Releases / 11 Oct 2019

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019

Press Releases / 07 Oct 2019

Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection

Press Releases / 03 Oct 2019

Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care

Press Releases / 25 Sep 2019

Summit to Host R&D Day 7 October 2019

Press Releases / 24 Sep 2019

Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019

Press Releases / 18 Sep 2019

Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes

Press Releases / 05 Sep 2019

Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference

Press Releases / 01 Aug 2019

Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Press Releases / 17 Jul 2019

Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress

Press Releases / 09 Jul 2019

Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia

<< 1 2 3 … 26 27 >>